Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 17, 2015, 76 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $32.20 to $7,735,729,234.17.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Gardiner Nathaniel S., who is Sr. VP & General Counsel at Enanta Pharmaceuticals, bought 1,400 shares at $33.23 on Feb. 17, 2015. Following this transaction, the Sr. VP & General Counsel owned 1,400 shares meaning that the stake was boosted by 100% with the 1,400-share transaction.

The shares most recently traded at $33.70, up $0.47, or 1.39% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 4,500
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 40,500
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 69,500

The average volume for Enanta Pharmaceuticals has been 417,900 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $622.1 million and is part of the health care sector and drugs industry. Shares are down 35.2% year-to-date as of the close of trading on Tuesday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 7.8. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings

rates Enanta Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Enanta Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Federal Agricultural Mortgage (AGM) - FREE Research Report

Junkins Lowell, who is Director at Federal Agricultural Mortgage, sold 250 shares at $32.00 on Feb. 17, 2015. Following this transaction, the Director owned 11,439 shares meaning that the stake was reduced by 2.14% with the 250-share transaction.

The shares most recently traded at $32.70, up $0.70, or 2.14% since the insider transaction. Historical insider transactions for Federal Agricultural Mortgage go as follows:

  • 4-Week # shares bought: 100
  • 4-Week # shares sold: 620
  • 12-Week # shares bought: 100
  • 12-Week # shares sold: 620
  • 24-Week # shares bought: 100
  • 24-Week # shares sold: 2,840

The average volume for Federal Agricultural Mortgage has been 37,000 shares per day over the past 30 days. Federal Agricultural Mortgage has a market cap of $304.2 million and is part of the financial sector and financial services industry. Shares are up 7.28% year-to-date as of the close of trading on Tuesday.

Federal Agricultural Mortgage Corporation provides a secondary market for various loans made to borrowers in the United States. The company operates in three segments: Farm & Ranch, USDA Guarantees, and Rural Utilities. The stock currently has a dividend yield of 1.98%. The company has a P/E ratio of 8.1. Currently, there is 1 analyst who rates Federal Agricultural Mortgage a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AGM - FREE

TheStreet Quant Ratings

rates Federal Agricultural Mortgage as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full

Federal Agricultural Mortgage Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Lakeland Financial (LKFN) - FREE Research Report

De Batty Jill A, who is Senior Vice President at Lakeland Financial, sold 1,100 shares at $39.55 on Feb. 17, 2015. Following this transaction, the Senior Vice President owned 2,542 shares meaning that the stake was reduced by 30.2% with the 1,100-share transaction.

The shares most recently traded at $39.36, down $0.19, or 0.49% since the insider transaction. Historical insider transactions for Lakeland Financial go as follows:

  • 4-Week # shares bought: 970
  • 4-Week # shares sold: 16,243
  • 12-Week # shares bought: 1,091
  • 12-Week # shares sold: 16,243
  • 24-Week # shares bought: 1,667
  • 24-Week # shares sold: 16,243

The average volume for Lakeland Financial has been 47,300 shares per day over the past 30 days. Lakeland Financial has a market cap of $656.1 million and is part of the financial sector and banking industry. Shares are down 8.56% year-to-date as of the close of trading on Tuesday.

Lakeland Financial Corporation operates as the holding company for Lake City Bank that provides various commercial and retail banking, wealth advisory, and investment brokerage services to individuals and businesses in Indiana, the United States. The stock currently has a dividend yield of 2.12%. The company has a P/E ratio of 15.4. Currently, there are 3 analysts who rate Lakeland Financial a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LKFN - FREE

TheStreet Quant Ratings

rates Lakeland Financial as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Lakeland Financial Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null